Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INCY with free AI briefings, catalyst countdowns, and dilution alerts.

INCY · INCYTE CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.9B Cash on Hand
137.9mo Cash Runway
Follow INCY by email Get an email when INCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INCY, unsubscribe in one click. Privacy

📣 What INCY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ruxolitinib
FDA approved Nov 2011 · Jakafi
Graft-versus-host Disease (GVHD) Phase 3 · NCT06615050 Recruiting
Axatilimab (INCA034176)
FDA approved Aug 2024 · Niktimvo
Chronic Graft-versus-host-disease Phase 3 · NCT06585774 Recruiting
Pemigatinib
FDA approved Apr 2020 · Pemazyre
Bladder Cancer Phase 2 · NCT03914794 Active not recruiting
Retifanlimab
FDA approved Mar 2023 · Zynyz
Neurofibromatosis Type 2 Phase 2 · NCT04374305 Recruiting
Investigator's choice of chemotherapy Solid Tumors Phase 3 · NCT07522073 Recruiting
KRAS G12D Inhibitor INCB161734 Solid Tumors Phase 3 · NCT07522073 Recruiting
CDK2 Inhibitor INCB123667 Ovarian Cancer Phase 3 · NCT07214779 Active not recruiting
Povorcitinib Hidradenitis Suppurativa (HS) Phase 3 · NCT06855498 Recruiting
Anti-PD-1/Anti-TGFbRII Bispecific Antibody… CRC (Colorectal Cancer) Phase 3 · NCT07284849 Recruiting
Anti-mutant Calreticulin Monoclonal Antibody… Essential Thrombocythemia Phase 3 · NCT07623200 Recruiting
FOLFOX CRC (Colorectal Cancer) Phase 3 · NCT07284849 Recruiting
Ruxolitinib Phosphate Cream NonSegmental Vitiligo Phase 3 · NCT06804811 Recruiting
Therapeutic Corticosteroid Chronic Graft-versus-host-disease Phase 3 · NCT06585774 Recruiting
Parsaclisib Non Hodgkins Lymphoma Phase 1/2 · NCT04661007 Active not recruiting
Ponatinib Acute Myeloid Leukemia Phase 1/2 · NCT03934372 Recruiting
JAK Inhibitor Myelodysplastic/Myeloproliferative Neoplasm Phase 2 · NCT07228624 Recruiting

Also used in these trials (approved or third-party drugs, not INCY's own candidates): Lenalidomide, Cyclophosphamide, Tacrolimus Extended-Release, Tafasitamab, Bevacizumab, Methotrexate, Mycophenolate Mofetil, Nivolumab, Pembrolizumab, Rituximab, Tazemetostat, Azacitidine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INCY holds $3.9B in cash and short-term investments (as of Sep 30, 2026) and burns about $83.8M/quarter from operations, an estimated runway of 137.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INCY files for a raise →

👥 Who Owns INCY

Insiders 0.5% Institutions (1344 holders) 99.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Felix J. Baker Institution (13G, 5%+) 31,225,572 15.32% 2026-05-07
Vanguard Capital Management Institution (13G, 5%+) 12,591,630 6.18% 2026-03-31
BAKER BROS. ADVISORS LP
Director, 10% owner · +6,111 options
Insider 314,600 0.15% 2026-09-30
Pablo J Cagnoni
President, Global Head of R&D · +136,325 options
Insider 183,200 0.09% 2026-10-15
William Meury
Chief Executive Officer, Director · +157,569 options
Insider 183,129 0.09% 2026-07-16
Mohamed Khairie Issa
EVP, Head of U.S. Commercial · +53,561 options
Insider 71,797 0.04% 2026-07-16
Patrick A Mayes
EVP & Chief Scientific Officer · +48,885 options
Insider 61,441 0.03% 2026-08-05
Lee Heeson
EVP, Head of Incyte Intl · +28,921 options
Insider 37,578 0.02% 2026-10-01
Steven H Stein
CMO & Head of Late-Stage Dev. · +131,582 options
Insider 30,916 0.02% 2026-11-06
Paul J Clancy
Director · +6,111 options
Insider 25,838 0.01% 2026-09-30
Edmund Harrigan
Director · +6,111 options
Insider 23,225 0.01% 2026-09-30
Thomas Tray
Principal Accounting Officer · +4,079 options
Insider 21,126 0.01% 2026-11-03

Share count 203,832,492 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full INCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.